Nanotechnology has revolutionized fundamental opportunities for higher specific drug delivery
with minimum side effects. Since its inception, the goal of nanotechnology has been to advance effective and
reliable systems for precise anti-cancer therapy and diagnosis. To accomplish this goal, bio-conjugation
strategies of therapeutic agents loaded nanoparticles with monoclonal antibodies or their analogues have
demonstrated a targeted approach both in vitro and in vivo. In this review, we primarily focus on the specific
recognition of HER2 receptors of HER2 overexpressed tumor cells, and evaluate anti-HER2 monoclonal antibody as an
effective tool for active targeting. Currently, a variety of nanoparticle systems are under both preclinical and clinical trials
for targeting to HER2 positive breast cancer. Different nanotechnology scaffolds including liposomes, dendrimers,
micelles, polymeric and inorganic nanoparticles that have higher flexibility for macromolecular synthesis and versatile
functionalizing properties have been reviewed in this study. Continuing advances in anti-HER2 functionalized
nanoparticles have good potential to lead to the development of nano-therapy against HER2 positive breast cancer.
Keywords: Breast cancer, dendrimer, HER2, liposome, micelles, nanoparticle, PLGA.
Rights & PermissionsPrintExport